share_log

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K：重大事件
美股SEC公告 ·  07/30 17:02

Moomoo AI 已提取核心訊息

On July 24, 2024, Panbela Therapeutics, Inc. and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., entered into a Loan Agreement with USWM, LLC, securing a term loan of $1.5 million. The loan, evidenced by a Term Promissory Note, is due by the earlier of a Qualifying Financing, a Qualifying Transaction, or December 31, 2024. The loan bears interest and a premium, with a maximum Qualifying Transaction Payment capped at $1 million. The proceeds are designated for specific uses, including payment to a contract research organization and other working capital needs. The Loan Agreement includes standard covenants and events of default, and the company has pledged to complete a Qualifying Financing by the end of 2024 and a Qualifying Transaction by July 24, 2025. To secure the loan, Panbela Therapeutics and its subsidiary granted a first priority security interest in their rights in an Asset Purchase Agreement to the lender. The full texts of the Loan Agreement, Term Note, and Security Agreement were filed with the SEC and are incorporated by reference into this report.
On July 24, 2024, Panbela Therapeutics, Inc. and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., entered into a Loan Agreement with USWM, LLC, securing a term loan of $1.5 million. The loan, evidenced by a Term Promissory Note, is due by the earlier of a Qualifying Financing, a Qualifying Transaction, or December 31, 2024. The loan bears interest and a premium, with a maximum Qualifying Transaction Payment capped at $1 million. The proceeds are designated for specific uses, including payment to a contract research organization and other working capital needs. The Loan Agreement includes standard covenants and events of default, and the company has pledged to complete a Qualifying Financing by the end of 2024 and a Qualifying Transaction by July 24, 2025. To secure the loan, Panbela Therapeutics and its subsidiary granted a first priority security interest in their rights in an Asset Purchase Agreement to the lender. The full texts of the Loan Agreement, Term Note, and Security Agreement were filed with the SEC and are incorporated by reference into this report.
2024年7月24日，Panbela Therapeutics公司及其子公司Cancer Prevention Pharmaceuticals公司與USWm LLC簽訂貸款協議，獲得150萬美元的貸款。該貸款由一份期限本票證明，並在資格融資、資格交易或2024年12月31日以前到期。該貸款帶有利息和溢價，最大的資格交易支付上限爲100萬美元。所得資金專項用途確定，包括支付合同研究機構和其他營運資本需求。貸款協議包括標準契約和違約事件，公司已承諾於2024年底完成資格融資，並於2025年7月24日之前完成資格交易。爲保障貸款，Panbela Therapeutics及其子公司向貸方授予了資產購買協議中其權利的第一優先安全利益。該貸款協議、期限票據和安全協議的全部文字已提交給證券交易委員會，並被引用爲本報告的一部分。
2024年7月24日，Panbela Therapeutics公司及其子公司Cancer Prevention Pharmaceuticals公司與USWm LLC簽訂貸款協議，獲得150萬美元的貸款。該貸款由一份期限本票證明，並在資格融資、資格交易或2024年12月31日以前到期。該貸款帶有利息和溢價，最大的資格交易支付上限爲100萬美元。所得資金專項用途確定，包括支付合同研究機構和其他營運資本需求。貸款協議包括標準契約和違約事件，公司已承諾於2024年底完成資格融資，並於2025年7月24日之前完成資格交易。爲保障貸款，Panbela Therapeutics及其子公司向貸方授予了資產購買協議中其權利的第一優先安全利益。該貸款協議、期限票據和安全協議的全部文字已提交給證券交易委員會，並被引用爲本報告的一部分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間